Literature DB >> 31589052

MHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics.

Leon Bichmann, Annika Nelde, Michael Ghosh, Lukas Heumos, Christopher Mohr, Alexander Peltzer, Leon Kuchenbecker, Timo Sachsenberg, Juliane S Walz, Stefan Stevanović1, Hans-Georg Rammensee1, Oliver Kohlbacher2.   

Abstract

Personalized multipeptide vaccines are currently being discussed intensively for tumor immunotherapy. In order to identify epitopes-short, immunogenic peptides-suitable for eliciting a tumor-specific immune response, human leukocyte antigen-presented peptides are isolated by immunoaffinity purification from cancer tissue samples and analyzed by liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS). Here, we present MHCquant, a fully automated, portable computational pipeline able to process LC-MS/MS data automatically and generate annotated, false discovery rate-controlled lists of (neo-)epitopes with associated relative quantification information. We could show that MHCquant achieves higher sensitivity than established methods. While obtaining the highest number of unique peptides, the rate of predicted MHC binders remains still comparable to other tools. Reprocessing of the data from a previously published study resulted in the identification of several neoepitopes not detected by previously applied methods. MHCquant integrates tailor-made pipeline components with existing open-source software into a coherent processing workflow. Container-based virtualization permits execution of this workflow without complex software installation, execution on cluster/cloud infrastructures, and full reproducibility of the results. Integration with the data analysis workbench KNIME enables easy mining of large-scale immunopeptidomics data sets. MHCquant is available as open-source software along with accompanying documentation on our website at https://www.openms.de/mhcquant/ .

Entities:  

Keywords:  HLA immunopurification; MHC binding prediction; bioinformatics; immunopeptidomics; mass spectrometry; neoepitopes

Year:  2019        PMID: 31589052     DOI: 10.1021/acs.jproteome.9b00313

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  9 in total

1.  Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.

Authors:  Michael Ghosh; Marion Gauger; Ana Marcu; Annika Nelde; Monika Denk; Heiko Schuster; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Mol Cell Proteomics       Date:  2020-01-14       Impact factor: 5.911

2.  Database search engines and target database features impinge upon the identification of post-translationally cis-spliced peptides in HLA class I immunopeptidomes.

Authors:  Michele Mishto; Yehor Horokhovskyi; John A Cormican; Xiaoping Yang; Steven Lynham; Henning Urlaub; Juliane Liepe
Journal:  Proteomics       Date:  2022-03-03       Impact factor: 5.393

3.  Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis.

Authors:  Bo Wen; Kai Li; Yun Zhang; Bing Zhang
Journal:  Nat Commun       Date:  2020-04-09       Impact factor: 14.919

4.  HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.

Authors:  Ana Marcu; Leon Bichmann; Leon Kuchenbecker; Daniel Johannes Kowalewski; Lena Katharina Freudenmann; Linus Backert; Lena Mühlenbruch; András Szolek; Maren Lübke; Philipp Wagner; Tobias Engler; Sabine Matovina; Jian Wang; Mathias Hauri-Hohl; Roland Martin; Konstantina Kapolou; Juliane Sarah Walz; Julia Velz; Holger Moch; Luca Regli; Manuela Silginer; Michael Weller; Markus W Löffler; Florian Erhard; Andreas Schlosser; Oliver Kohlbacher; Stefan Stevanović; Hans-Georg Rammensee; Marian Christoph Neidert
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

5.  Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues.

Authors:  Peter Kubiniok; Ana Marcu; Leon Bichmann; Leon Kuchenbecker; Heiko Schuster; David J Hamelin; Jérôme D Duquette; Kevin A Kovalchik; Laura Wessling; Oliver Kohlbacher; Hans-Georg Rammensee; Marian C Neidert; Isabelle Sirois; Etienne Caron
Journal:  iScience       Date:  2022-01-18

6.  IntroSpect: Motif-Guided Immunopeptidome Database Building Tool to Improve the Sensitivity of HLA I Binding Peptide Identification by Mass Spectrometry.

Authors:  Le Zhang; Geng Liu; Guixue Hou; Haitao Xiang; Xi Zhang; Ying Huang; Xiuqing Zhang; Bo Li; Leo J Lee
Journal:  Biomolecules       Date:  2022-04-14

7.  MS2Rescore: Data-Driven Rescoring Dramatically Boosts Immunopeptide Identification Rates.

Authors:  Arthur Declercq; Robbin Bouwmeester; Aurélie Hirschler; Christine Carapito; Sven Degroeve; Lennart Martens; Ralf Gabriels
Journal:  Mol Cell Proteomics       Date:  2022-07-06       Impact factor: 7.381

8.  Empirical Evaluation of the Use of Computational HLA Binding as an Early Filter to the Mass Spectrometry-Based Epitope Discovery Workflow.

Authors:  Rachid Bouzid; Monique T A de Beijer; Robbie J Luijten; Karel Bezstarosti; Amy L Kessler; Marco J Bruno; Maikel P Peppelenbosch; Jeroen A A Demmers; Sonja I Buschow
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

9.  The Choice of Search Engine Affects Sequencing Depth and HLA Class I Allele-Specific Peptide Repertoires.

Authors:  Robert Parker; Arun Tailor; Xu Peng; Annalisa Nicastri; Johannes Zerweck; Ulf Reimer; Holger Wenschuh; Karsten Schnatbaum; Nicola Ternette
Journal:  Mol Cell Proteomics       Date:  2021-07-23       Impact factor: 5.911

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.